Acumen Pharmaceuticals Eyes Late 2026 Data for Alzheimer’s Drug as Cash Runs Thin — Acumen Pharmaceuticals, Inc.

Event summary

Acumen Pharmaceuticals reported $116.9M in cash as of Dec. 31, 2025, down from $136.1M three months prior, with runway into early 2027.
Topline results from the Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer’s disease are expected in late 2026.
The company raised $35.75M in a private placement in March 2026 to advance its Enhanced Brain Delivery (EBD) program.
R&D expenses rose to $104.9M in 2025 from $93.8M in 2024, driven by ALTITUDE-AD trial costs and EBD research.

The big picture

Acumen Pharmaceuticals is betting heavily on its lead candidate, sabirnetug, with Phase 2 data due in late 2026. The company’s financial position remains precarious, with cash expected to last into early 2027. Success in the ALTITUDE-AD trial could position Acumen as a key player in Alzheimer’s treatment, but failure risks derailing its pipeline momentum. The $35.75M private placement in March 2026 suggests confidence in the EBD program, though execution risks remain high.

What we're watching

Clinical Trial Outcomes: Whether the ALTITUDE-AD trial results in late 2026 will validate sabirnetug’s efficacy in early Alzheimer’s disease.
Financial Runway: The pace at which Acumen burns through its remaining $116.9M in cash and whether additional funding will be necessary before 2027.
Pipeline Progress: How the EBD program advances toward an IND filing in mid-2027 and its potential to differentiate Acumen’s Alzheimer’s treatment approach.